Current state of symptomatic aortic valve stenosis in the japanese elderly

Circulation Journal

Volumn 75, Issue 10, 2011, Pages 2474-2481

  Ohno, Masakazu ^a,b   Hashimoto, Yuji ^a   Suzuki, Makoto ^a   Matsumura, Akihiko ^a   Isobe, Mitsuaki ^b  

^a KAMEDA MEDICAL CENTER   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Aging; Aortic stenosis; Japanese; Prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; HEMOGLOBIN;

AGED; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG USE; FEMALE; FLOW RATE; GERIATRIC PATIENT; HEART DEATH; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; PRESSURE GRADIENT; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SYMPTOM;

AGE FACTORS; AGED; AGED, 80 AND OVER; AORTIC VALVE; AORTIC VALVE STENOSIS; ELECTROCARDIOGRAPHY; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; OBSERVATION; PROGNOSIS;

EID: 80053123751     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0012     Document Type: Article

References (40)

1. th edn. Philadelphia: Saunders, 2008; 1625-1635.
2. Akins CW, Dagget WM, Vlahakes GJ, Hilgenverg AD, Torchiana DF, Madsen JC, et al. Cardiac operations in patients 80 years old and older. Ann Thorac Surg 1997; 64: 606-614.
3. Medalion B, Lytle BW, McCarthy PM, Stewart RW, Arheart KL, Arnold JH, et al. Aortic valve replacement for octogenarians: Are small valves bad? Ann Thorac Surg 1998; 66: 699-705.
4. Kolh P, Kerzman A, Lahaye L, Gerard P, Limet R. Cardiac surgery in octogenarians: Peri-operative outcome and long-term results. Eur Heart J 2001; 22: 1235-1243.
5. Roberts WC, Ko JM, Garner WL, Filardo G, Henry AC, Hebeler RF Jr, et al. Valve structure and survival in octogenarians having aortic valve replacement for aortic senosis (+/aortic regurgitation) with versus without coronary artery bypass grafting at a single US medical center (1993 to 2005). Am J Cardiol 2007; 100: 489-495.
6. Iung B. Management of the elderly patient with aortic stenosis. Heart 2008; 94: 519-524.
7. Kojodjojo P, Gohil N, Barker D, Youssefi P, Salukhe TV, Choong A, et al. Outcomes of elderly patients aged 80 and over with symptomatic, severe aortic stenosis: Impact of patient's choice of refusing aortic valve replacement on survival. QJM 2008; 101: 567-573.
8. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiotorac Surg 1999; 16: 9-13.
9. Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. Eur Heart J 2003; 24: 881-882.
10. Abridged Life Table for Male in 2009, Ministry of Health, Labour and Welfare. http://www.mhlw.go.jp/toukei/saikin/hw/life/life09/hyo-m.html (accessed 15 November, 2010).
11. Abridged Life Table for Female in 2009, Ministry of Health, Labour and Welfare. http://www.mhlw.go.jp/toukei/saikin/hw/life/life09/hyo-f.html (accessed 15 November, 2010).
12. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363: 1597-1607.
13. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001; 88: 693-695.
14. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001; 104: 2205-2209.
15. Pedersen TR. Intensive lipid-lowering therapy for patients with aortic stenosis. Am J Cardiol 2008; 102: 1571-1576.
16. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriques-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002; 40: 1723-1730.
17. Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Gonçalves F, et al. Rosuvastatin sffecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007; 49: 554-561.
18. Cowell SJ, Newby DE, Prescott RJ, Bloomfiled P, Reid J, Northridge DB, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352: 2389-2397.
19. Rosseb AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Eqstrup K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343-1356.
20. Chan KL, Teo K, Dumensnil JG, Ni A, Tam J; Astronomer investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: Results of aortic stenosis progression observation: Measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010; 121: 306-314.
21. Tsuchida M, Kawashima MA, Tada H, Takata M, Nohara A, Ino H, et al. Marked aortic valve stenosis progression after receiving longterm aggressive cholesterol-lowering therapy using low-density lipoprotein apheresis in a patient with familial hypercholesterolemia. Circ J 2009; 73: 963-966.
22. Heistad DD, Wakisaka Y, Miller J, Chu Y, Pena-Silva R. Novel aspects of oxidative stress in cardiovascular diseases. Circ J 2009; 73: 201-207.
23. Guidelines for Surgical and Interventional Treatment of Valvular Heart Disease (JCS 2007). http://www.j-circ.or.jp/guideline/pdf/JCS2007_mastuda_h.pdf (accessed 6 May, 2010).
24. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, et al. 2008 focused update incorporated into the ACC/ AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angioplasty and interventions, and Society of Thoracic Surgeons. Circulation 2008; 118: e523-e661.
25. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Euro Heart J 2007; 28: 230-268.
26. Edwards FH, Peterson ED, Coombs LP, Delong ER, Jamieson WR, Shroyer ALW, et al. Prediction of operative mortality after valve replacement surgery, J Am Coll Cardiol 2001; 37: 885-892.
27. Society of Thoracic Surgeons National Cardiac Surgery Database. http://www.sts.org/documents/pdf/ndb2010/20093rdHarvestExecutiveSummary. pdf (accessed 6 May, 2010).
28. Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, et al. Natriuretic peptides predict sympom-free survival and postoperative outcome in severe arotic stenosis. Circulation 2004; 109: 2302-2308.
29. Nessmith MG, Fukuta H, Brucks S, Little WC. Usefulness of an elevated B-type natriuretic peptide in predicting survival in patients with aortic stenosis treated without surgery. Am J Cardiol 2005; 96: 1445-1448.
30. Pedrazzini GB, Masson S, Latini R, Klersy C, Rossi MG, Pasotti E, et al. Comparison of brain natriuretic peptide plasma levels versus logistic EuroSCORE in predicting in-hospital and late postoperative mortality in patients undergoing aortic valve replacement for symptomatic aortic stenosis. Am J Cardiol 2008; 102: 749-754.
31. Ohara T, Hashimoto Y, Matsumura M, Suzuki M, Isobe M. Accelerated progression and morbidity in patients with aortic stenosis on chronic dialysis. Circ J 2005; 69: 1535-1539.
32. Iung B, Baron G, Burchart EF, Delahaye F, Gohlke-Bärwolf C, Levang OW, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on valvular heart disease. Eur Heart J 2003; 24: 1231-1243.
33. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, et al. Percutaneous transcatheter implantaion of an aortic valve prosthesis for calcific aortic stenosis: First human case description. Circulation 2002; 106: 3006-3008.
34. Hara H, Schwarts RS. Transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis. Circ J 2010; 74: 1513-1517.
35. Webb JG, Chandavimol M, Thompson CR, Ricci DR, Carere RG, Munt BI, et al. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 2006; 113: 842-850.
36. Petronio AS, De Carlo M, Bedogni F, Marzocchi A, Klugmann S, Maisano F, et al. Safety and efficacy of the subclavian approach for transcatheter aortic valve implantation with the CoreValve revalving system. Circ Cardiovasc Interv 2010; 3: 359-366.
37. Ye J, Cheung A, Lichtenstein SV, Carere RG, Thompson CR, Pasupati S, et al. Transapical aortic valve implantation in humans. J Thorac Cardiovasc Surg 2006; 131: 1194-1196.
38. Spaccarotella C, Mongiardo A, Indolfi C. Pathophysiology of aortic stenosis and approach to treatment with percutaneous valve implantation. Circ J 2011; 75: 11-19.
39. Thomas M, Schymik G, Walther T, Himbert D, Lefèvre T, Treede H, et al. Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: A European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 2010; 122: 62-69.
40. Clinical Trials.gov. Transfemoral & Transapical Placement of Aortic Balloon Expandable Transcatheter Valves Trial (JAPAN) (PREVAIL JAPAN). http://clinicaltrials.gov/ct2/show/study/NCT01113983 (accesed 25 March, 2011).